ArticleTranslational cancer research2026
SUMOylation of UBE2C facilitates hepatocellular carcinoma proliferation and invasion via the MAPK pathway.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) remains a major cause of cancer mortality worldwide, with limited treatment efficacy due to frequent recurrence and therapeutic resistance. UBE2C, a ubiquitin-conjugating enzyme, has been implicated in various cancers, but its regulatory mechanisms and oncogenic roles in HCC are not well defined. Therefore, the objective of this study was to systematically investigate the expression pattern, biological function, and underlying molecular mechanisms of UBE2C in HCC, with the aim of elucidating its role in tumor progression and exploring its potential as a therapeutic target. Methods: We integrated transcriptomic data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases to identify genes that are differentially expressed in HCC. UBE2C expression was validated in tissues and cell lines by quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting. The functional roles of these genes were assessed via proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) assays. Chromatin immunoprecipitation quantitative polymerase chain reaction (ChIP-qPCR) and luciferase assays confirmed that MYBL2 binds to the UBE2C promoter. SUMOylation at UBE2C lysine 18 (K18) was examined using site-directed mutagenesis and coimmunoprecipitation. Downstream signalling was explored through transcriptomic profiling, pathway enrichment, and MAPK pathway activity analysis. Rescue experiments were performed with the MAPK inhibitor trametinib. Results: UBE2C was highly expressed in HCC and correlated with poor prognosis. Knockdown of UBE2C suppressed cell proliferation, migration, and EMT. MYBL2 transcriptionally activated UBE2C, whereas UBC9-mediated SUMOylation at K18 increased its protein stability. UBE2C overexpression activated the MAPK signalling cascade by upregulating PRKCB and PLCG2 expression, leading to increased phosphorylation of RAF, MEK, and ERK. MAPK inhibition attenuated UBE2C-induced oncogenic effects. Conclusions: We reveal a novel oncogenic axis in which MYBL2 and SUMOylation cooperatively increase UBE2C expression and stability, promoting HCC progression via MAPK pathway activation. Targeting the MYBL2/UBE2C/MAPK axis represents a potential therapeutic strategy for treating HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.